Tag: Thrombotic thrombocytopenic purpura

Without treatment, thrombotic thrombocytopenic purpura (TTP) has a mortality rate exceeding 90% [1.4.7]. While modern treatments have dramatically improved survival, a key question remains for many: **Is rituximab FDA approved for TTP?** The answer is no, but its role is critical [1.2.1, 1.3.1].

There is no single "drug of choice" for purpura, as treatment depends entirely on the underlying cause, which can range from autoimmune disorders to infections or even the use of certain medications. For instance, one of the most common types in adults, immune thrombocytopenia (ITP), is often initially treated with corticosteroids.

Ticlopidine was notably associated with a risk of severe hematological adverse reactions, such as neutropenia and thrombotic thrombocytopenic purpura (TTP), which ultimately led to its discontinuation in the United States and other regions. This article details what type of drug is ticlopidine, its mechanism of action, and why it is no longer widely used.

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare but life-threatening blood disorder, and the use of rituximab has fundamentally changed its prognosis. Understanding **why rituximab for TTP** is so effective involves delving into its targeted mechanism against the autoimmune cause of the disease.